Do U.S. cancer drug sales reflect clinical benefit? Evidence from solid tumor drugs from 2008 to 2022
Although prior studies have found little relationship between cancer drug prices and clinical benefit, our findings indicate that net sales, reflecting both price and use, are significantly higher for drugs with substantial clinical benefit. This suggests that the U.S. cancer drug market rewards meaningful innovation through higher market uptake, even in the absence of clear price signals.
Authors
- Mikael Svensson (ORCID: https://orcid.org/0000-0003-1113-7478)
- Sumaya Abuloha (ORCID: https://orcid.org/0000-0003-4742-6212)
- Melissa Miri
- Benjamin P. Harvey
- Shu Niu
- Alaa Alshehri
Institutions
- American Association of Colleges of Pharmacy (US)
- University of Florida (US)
- Imam Abdulrahman Bin Faisal University (SA)
- Yarmouk University (JO)
- University of Gothenburg (SE)
Publication Details
- Journal
- Journal of Cancer Policy
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1016/j.jcpo.2026.100723
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00